Hospital Pharmacies accounted for a 50.5% share of the osteoarthritis injectables market in 2025, reflecting their leading role in treatment delivery for injectable therapies that are often administered within structured clinical settings. This segment maintains its share because osteoarthritis injectables are closely tied to physician oversight, hospital-based prescribing pathways, and coordinated patient management, particularly where administration timing, product handling, and follow-up are important. Hospital pharmacies also benefit from being embedded within care environments where diagnosis, consultation, and injection procedures are commonly linked, helping sustain their leadership in the osteoarthritis injectables market.

Retail Pharmacies are emerging as the fastest-growing end-use segment in the osteoarthritis injectables market as treatment access increasingly extends beyond hospital-centered dispensing channels. Growth is being reinforced through patient demand for more convenient refill and purchase options, especially for therapies used in ongoing osteoarthritis management. Compared with hospital pharmacies, retail pharmacies are gaining momentum because they align better with decentralized care patterns and routine outpatient engagement, making them a more accessible channel as treatment pathways become more flexible.

Anatomy Segment Analysis: Knee Osteoarthritis (Largest Segment) vs Hip Osteoarthritis (Fastest-Growing Segment)

In 2025, Knee Osteoarthritis held a 44.48% share of the osteoarthritis injectables market, making it the leading anatomy segment. Its leadership is underpinned by the high treatment relevance of injectable therapies in knee-related disease management, where joint pain, mobility limitations, and repeated clinical intervention often support continued use of injectables. The knee is also a frequent focus of non-surgical symptom management, which helps preserve strong procedure volumes and steady demand within the osteoarthritis injectables market.

Hip Osteoarthritis represents the fastest-growing anatomy segment in the osteoarthritis injectables market, encouraged by rising use of injectable options in cases where patients seek symptom relief before moving to more invasive treatment routes. This segment is gaining momentum relative to other anatomical categories because hip-related osteoarthritis management increasingly requires alternatives that can fit into staged care approaches, especially when preserving function and delaying procedural escalation are practical priorities. That dynamic is strengthening adoption of injectables for hip osteoarthritis across relevant care settings.